See references below for related reading.
13.1 Bringing in-vivo considerations into NMS design
13.1.1 the in-vitro to ex-vivo to in-vivo paradigm
184.108.40.206 In-vitro - importance of choosing suitable cell lines
220.127.116.11 adding the complexity of in-vivo background while keeping the simplicity of in-vitro
18.104.22.168 all the complexity of ex-vivo plus the “active” components of a real animal
13.1.2 In-vivo systems are open, “active” systems with multiple layers of complexity
22.214.171.124 In-vitro and ex-vivo are mostly “closed” systems, but not absolutely
126.96.36.199 What is an “open” system?
188.8.131.52 Attempts to isolate open systems
13.1.3 Layers of complexity of in-vivo systems
184.108.40.206 Human cells in nude mice – a mixture of in-vitro and in-vivo
220.127.116.11 “Model” small animal systems
18.104.22.168 better model larger animal systems
13.2 Circulation time and biodistribution
13.2.1 factors affecting circulation time
22.214.171.124 "stealth layer" coating
126.96.36.199 zeta potential in-vivo in varying environments
188.8.131.52 filtration and excretion
13.2.2 where do the NMS go in-vivo?
184.108.40.206 checking the obvious organs (liver, spleen, kidney, blood…)
220.127.116.11 finding NMS in tissues and organs
18.104.22.168.2 within dissected tissue sections
22.214.171.124.3 in blood (ex-vivo versus in-vivo flow cytometry)
126.96.36.199.4 what is excreted?
13.2.3 Circulation time and dose optimization
188.8.131.52 measure drug concentration over time
184.108.40.206 is there an optimal drug dose?
13.4 In-vivo targeting and mistargeting
13.4.1 mode of administration (intravenous, oral, intra-tumor…)
13.4.2 how can we assess targeting in-vivo? (MRI, fluorescence, …)
13.4.3 a rare-cell targeting problem
13.4.4 consequences of mistargeting
13.4.5 balancing dosing, therapeutic efficacy, and consequences of mistargeting
13.5 Evaluating therapeutic efficacy in-vivo
13.5.1 advantages of non-invasive measurements
13.5.2 measures of tumor load/shrinkage (tumor size, weight,..)
13.5.3 other measures of disease effects
220.127.116.11 direct measurement of restoration of lost or compromised functions
18.104.22.168 indirect measures of disease effects (e.g. behavior, weight gain/loss, .)
13.5.4 Some examples of in-vivo work with NMS
13.6.1 Choosing an appropriate animal model and getting it approved takes time!
13.6.2 Animal experiments are expensive and time-consuming
13.6.3 Performing in-vivo measurements of drug delivery and therapeutic efficacy are more challenging and expensive than in-vitro or ex-vivo work!
13.6.4 But ultimately you must show that the NMS works in-vivo
- Bhirde, A.A., Patel, V., Gavard, J., Zhang, G., Sousa, A.A., Masedunskas, A., Leapman, R.D., Weigert, R., Gutkind, J.S., Rusling, J.F. "Targeted Killing of Cancer Cells in Vivo and in Vitro with EGF-Directed Carbon Nanotube-Based Drug Delivery". ACS Nano 3(2) 307-316 (2009).
- Cartier, R., Kaufner, L., Paulke, B.R., Wustneck, R., Pietschmann, S., Michel, R., Bruhn, H., Pison, U. "Latex nanoparticles for multimodal imaging and detection in vivo". Nanotechnology 18:195102 – 195113 (2007).
- Chenga, J., Teply, B.A., Sherifia, I., Sunga, J., Luthera, G., Gua, F.X., Levy-Nissenbauma, E., Radovic-Morenob, A.F., Langer, R., Farokhzad, O.C. "Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery". Biomaterials 28: 869–876 (2007). (Full text available at nih.gov)
- Farokhzad, O.C., Cheng, J., Teply, B.A., Sherifi, I., Jon, S., Kantoff, P.W., Richie, J.P., Langer, R. "Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo". PNAS 103(6): 6313–6320 (2006).
- Hou, C-H, Hou, S-M, Hsueh, Y-S, Lin, J., Wu, H-C, Lin, F-H "The in vivo performance of biomagnetic hydroxyapatite nanoparticles in cancer hyperthermia therapy". Biomaterials 30: 3956–3960 (2009). (Full text available at nih.gov)
Researchers should cite this work as follows:
1083 BME, Purdue University, West Lafayette, IN
Use the error messages below to try and resolve the issue. If you are still unable to fix the problem report your problem to the system administrator by entering a support ticket.
- Unable to find presentation.